HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Tango Therapeutics, maintaining a price target of $13. Analyst Robert Burns continues to support the stock, indicating confidence in its potential growth.
October 28, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Tango Therapeutics, maintaining a price target of $13. Analyst Robert Burns continues to support the stock, indicating confidence in its potential growth.
The reiteration of a Buy rating and maintenance of a $13 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in stock price. The analyst's confidence suggests a strong belief in the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100